

Apelin-13 Regulates Angiotensin II-Induced Cx43 Downregulation and Autophagy via the AMPK/mTOR Signaling Pathway in HL-1 Cells

Yifan CHEN¹, Xi QIAO², Lijun ZHANG², Xuwen LI¹, Qinghua LIU²

¹Shanxi Bethune Hospital Affiliated to Shanxi Medical University, Taiyuan, China, ²Department of Pathophysiology, Shanxi Medical University, Taiyuan, China

Received April 18, 2020

Accepted August 1, 2020

Epub Ahead of Print September 9, 2020

Summary

Atrial fibrillation is associated with atrial remodeling, in which connexin 43 (Cx43) and cell hypertrophy play important roles. In this study, apelin-13, an aliphatic peptide, was used to explore the protective effects of the adenosine monophosphate-activated protein kinase (AMPK)/mTOR signaling pathway on Cx43 expression and autophagy, using murine atrial HL-1 cells. The expression of Cx43, AMPK, B-type natriuretic peptide (BNP) and pathway-related proteins was detected by Western blot analysis. Cellular fluorescence imaging was used to visualize Cx43 distribution and the cytoskeleton. Our results showed that the Cx43 expression was significantly decreased in HL-1 cells treated with angiotensin II but increased in cells additionally treated with apelin-13. Meanwhile, apelin-13 decreased BNP expression and increased AMPK expression. However, the expression of Cx43 and LC3 increased by apelin-13 was inhibited by treatment with compound C, an AMPK inhibitor. In addition, rapamycin, an mTOR inhibitor, promoted the development of autophagy, further inhibited the protective effect on Cx43 expression and increased cell hypertrophy. Thus, apelin-13 enhances Cx43 expression and autophagy *via* the AMPK/mTOR signaling pathway, and serving as a potential therapeutic target for atrial fibrillation.

Key words

Atrial fibrillation • Cx43 • Cell hypertrophy • AMPK/mTOR • Autophagy

Corresponding authors

X. Li, Shanxi Bethune Hospital Affiliated to Shanxi Medical University, 99 Longcheng Street, XiaoDian District, Taiyuan

030024, China. E-mail: xuwenli1010@126.com and Q. Liu, Department of Pathophysiology, Shanxi Medical University, 56 Xinjian South Road, Taiyuan 030001, China. E-mail: liuqh_w@sxmu.edu.cn

Introduction

Intercalated discs (IDs) are a specific structure in the heart muscle that play a crucial role in signal transduction. Gap junctions in the IDs allow many small molecules to pass through the cell membrane (Leybaert *et al.* 2017). Connexin 43 (Cx43), the major connexin in gap junctions, is highly expressed in cardiac muscle (Xiao *et al.* 2016). Gap junctions consist thousands intercellular channels composed of Cx43 and these channels are responsible for electrical and molecular signal propagation between cardiomyocytes. Therefore, the changes in topology of Cx43 or in the number of Cx43 channels which is largely determined by expression affect electrical properties of the myocardial tissue that promote arrhythmias, including AF.

Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia in clinical practice (Liu *et al.* 2013) with high morbidity and mortality rates and therefore associated with major health care costs (Chugh *et al.* 2014). Therefore, treatments that preserve Cx43 remodeling may represent a new strategy for AF management.

In 1998, Tatemoto *et al.* (1998) discovered a protein hormone from bovine stomach, which was later shown to have numerous biological functions, including a direct or indirect effect on cardiovascular physiology

(Lesui 2015). Numerous studies have indicated that apelin-13 exerts a cardioprotective effect in cardiac pathologies, including cardiac hypertrophy, fibroblast activation, vasoconstriction and myocardial infarction, but the relationship between apelin-13 and hypertrophy is not clear. Furthermore, apelin-13 was previously demonstrated to upregulate Cx43 remodeling under high-glucose conditions (Li *et al.* 2018). Thus, we assumed that apelin-13 plays a role in the regulation of atrial Cx43 expression and hypertrophy.

Autophagy is a catabolic process in which intracellular metabolites are engulfed by autophagosomes to promote cell renewal, recycling and maintain cellular homeostasis (Levine *et al.* 2004). In the heart, considerable evidence has shown that autophagy is involved in a series of physiological and pathological processes (Rockel *et al.* 2017). Even within the same cell, both up- and downregulation of autophagy can cause damage and ultimately lead to cell death. Another study found that decreased Cx43 expression had an inhibitory effect on cell survival, suggesting that Cx43 expression can alter cell-cell communication and contribute to apoptosis (Li *et al.* 2009). Several studies have indicated that the adenosine monophosphate-activated protein kinase (AMPK)/mTOR pathway, which is involved in numerous cellular processes, has a crucial effect on autophagy, affecting cell survival and death (Tang *et al.* 2016). Some publications reported that the AMPK/mTOR pathway participates in regulating cardiac Cx43 remodeling and autophagic flux, but few studies have evaluated the role of the AMPK/mTOR pathway in angiotensin II (AngII)-induced Cx43 dysfunction and hypertrophy and the protective effect conferred by apelin-13 on these mechanisms.

Here, we explored the potential protective effects of apelin-13 on AngII-induced Cx43 downregulation and cell hypertrophy *via* the AMPK/mTOR pathway in HL-1 cells. Our findings demonstrated that upregulation of autophagy inhibits cardiac Cx43 expression and increases cell hypertrophy.

Materials and Methods

Cell culture and experimental protocols

Murine HL-1 cells were cultured in high-glucose Dulbecco's modified Eagle medium (DMEM) containing 10 % fetal bovine serum (FBS, Biological Industries, USA) and 1 % penicillin/streptomycin solution in a humidified incubator containing 5 % CO₂ and 95 % air

at 37 °C. HL-1 cells were allowed to grow to approximately 85 % confluence and were then incubated for an additional 24 h under starvation conditions (without FBS). The cells were then treated with different concentrations of AngII (0.1, 1 and 10 μM, MedChemExpress, NJ, USA) alone or in combination with apelin-13 (10, 100 and 1000 nM, Santa Cruz Biotechnology, USA, for 48 h. Simultaneously, cells were treated with 10 μM compound C, dissolved in PBS, MedChemExpress), or the autophagy agonist rapamycin (MedChemExpress), dissolved in dimethyl sulfoxide (DMSO) and then diluted in high-glucose DMEM to a final concentration of 10 nM. The concentration of DMSO in cell medium was 1 %, which had no influence on cell viability. All drugs were freshly dissolved before each experiment.

Measurement of cell size

Upon reaching approximately 60 % confluence, HL-1 cells on slides were washed twice with PBS at 37 °C. The cultured cells were then fixed with 4 % formaldehyde for 10 min at room temperature. After three washings, the cells were treated with 0.5 % Triton X-100 for 5 min at room temperature. After washing three more times, the cells were incubated with 200 μl FITC-phalloidin diluted in 1 % biconchonic acid (BCA, Solarbio, Beijing, China) for 30 min at 37 °C. Finally, the cells were lightly washed and incubated with DAPI for approximately 30 s. A fluorescence microscope was used to visualize and photograph the HL-1 cells. Image J software was used to calculate the HL-1 cell surface area in each group.

Immunofluorescence staining

After treatment, the cells in each group were washed with 1× PBS three times and then fixed with 4 % formaldehyde for 15 min at room temperature. The cells were washed in PBS, blocked with 5 % goat serum for 1 h and incubated with a Cx43 antibody (1:100 dilution, ABclonal, Wuhan, China) overnight at 4 °C temperature. After three washes with PBS the following day, the cells were incubated with a secondary fluorescent antibody diluted 1:500 for 1 h. The cells were then washed again, and DAPI was incubated with the cell nuclei for approximately 15 min. Finally, the cells were visualized under a fluorescence microscope.

Western blot analysis

After harvesting HL-1 cells, proteins were

isolated by incubating in RIPA lysis buffer for approximately 30 min on ice. The resulting protein lysate was centrifuged at $12000\times g$ for 10 min. The BCA assay was used to measure the protein concentrations in each group, and 30-60 μg protein were resolved by 10 % sodium dodecyl sulfate polyacrylamide gel electrophoresis. The separated proteins were then transferred to polyvinylidene difluoride membranes. The membranes were blocked using 5 % non-fat dry milk or 5 % bovine serum albumin for 2 h at room temperature and incubated overnight at 4°C with primary antibodies against Cx43 (1:1000, Cell Signaling Technology), LC3B (1:1000, Cell Signaling Technology), p-AMPK, AMPK (1:1000, Sangon Biotech, Shanghai, China), mTOR (1:1000, Sigma-Aldrich) and B-type natriuretic peptide (BNP) (1:1000, Wanleibio, Shengyang, China). GAPDH was used as a loading control (1:3000, Sigma-Aldrich) in each case. The following day, the membranes were washed with TBST for 30 min and then incubated with HRP secondary antibodies for 2 h at room temperature. After three 10-min washes with TBST, the membranes were treated with an enhanced chemiluminescence kit and exposed to X-ray films. Image J software 6.0 was used to quantify all protein bands.

Statistical analysis

The data are expressed as means \pm standard error (SEM). Comparisons among groups were evaluated using one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test. Prism GraphPad 6.0 software (GraphPad Software Inc., San Diego, CA, USA) was used for the data analysis. $p < 0.05$ was considered to represent statistical significance.

Results

Apelin-13 restored the Cx43 downregulation induced by AngII in HL-1 cells

Cells were separately treated with AngII (0.1, 1 and $10\ \mu\text{M}$) (Fig. 1A) and apelin-13 (10, 100 and $1000\ \text{nM}$) (Fig. 1B) for 48 h. Treatment with $10\ \mu\text{M}$ AngII alone resulted in significant downregulation of Cx43 expression. Whereas treatment with apelin-13 alone at each concentration resulted in no change in Cx43 expression, when co-treated with $10\ \mu\text{M}$ AngII for 48 h, apelin-13 reversed the decrease in Cx43 induced by AngII. This protective effect of apelin-13 occurred in a concentration-dependent manner, peaking at $100\ \text{nM}$ (Fig. 1C).




Fig. 1. Effect of AngII and apelin-13 on Cx43 expression in HL-1 cells. AngII ($10\ \mu\text{M}$, 48 h) downregulated Cx43 expression (A), whereas apelin-13 ($100\ \text{nM}$, 48 h) had no significant effect on Cx43 expression at the various concentrations used (B). Subsequent incubation with both AngII and apelin-13 restored the Cx43 downregulation induced by AngII (C). Control: normal incubation; AngII: angiotensin II; AP: apelin-13. $n=5$; ** $p < 0.01$, vs. control; * $p < 0.05$, vs. AngII; # $p < 0.05$, vs. AngII.

Compound C and rapamycin inhibited AMPK expression and abolished the protective effect of apelin-13

As we found that apelin-13 had a stimulatory effect on AMPK expression, AMPK expression was measured in cells treated with compound C, an AMPK inhibitor, as a negative control. Rapamycin, a common activator of autophagy and inhibitor of mTOR activity, was also used to investigate the correlation between AMPK expression and autophagy. Under treatment with AngII and apelin-13, cells were additionally treated with compound C ($10\ \mu\text{M}$) and rapamycin ($10\ \text{nM}$) for 48 h, and the expression of AMPK was assessed by Western blot analysis. The results showed that both compound C and rapamycin significantly decreased AMPK expression, which was prevented by apelin-13 (Fig. 2A)




Fig. 2. The AMPK/mTOR signaling pathway was involved in autophagy of HL-1 cells. Compared with the control group, the expression of AMPK decreased (**A**) but mTOR and LC3II (**C**) increased (**B**) with AngII alone, whereas addition of AP reversed those change. Under treatment with AngII+AP, adding CC or Ra downregulated AMPK expression. mTOR expression increased with the addition of CC but decreased with the addition of Ra while LC3II expression decreased with the addition of CC but increased with the addition of Ra. $n=6$; * $p<0.05$; ** $p<0.01$.

Apelin-13 promoted autophagy via the AMPK/mTOR signaling pathway

To assess the effect of apelin-13 on autophagic activation in HL-1 cells and the role of the AMPK/mTOR signaling pathway in this effect, rapamycin (10 nM) and compound C (10 μ M) were used to disrupt AMPK/mTOR signaling, and the expression of mTOR and the autophagic marker LC3 was examined (Figs. 2B, C). Compared with AngII treatment alone, the expression of mTOR was decreased and that of LC3 increased in cells treated with both AngII and apelin-13. Remarkably, activation of autophagy was further promoted by rapamycin, as indicated by decreased mTOR expression and increased LC3II expression. However, compound C prevented apelin-13-induced autophagic activation, according to increased mTOR expression and decreased LC3II expression.

Apelin-13 reversed AngII-induced downregulation of Cx43 expression and distribution via the AMPK/mTOR signaling pathway

Apelin-13 prevented the downregulation of Cx43 expression induced by AngII (Fig. 3A). Compound C and rapamycin were used to determine whether this effect is mediated by the AMPK/mTOR signaling pathway. Cell immunofluorescence was also used to visualize the distribution and expression of Cx43 under the same treatment (Fig. 3B, C). Compared with AngII and apelin-13 treatment, adding additional compound C (10 μ M) or rapamycin (10 nM) decreased Cx43 expression and distribution, and rapamycin had a greater effect than compound C. These data further supported the correlation between Cx43 expression and AMPK/mTOR signaling pathway.




Fig. 3. The effects of compound C and rapamycin on Cx43 expression and distribution. Cx43 expression and distribution in HL-1 cells was determined by cell immunofluorescence and Western blot analysis. **(A)** Compared with the control group, Cx43 expression and distribution in the AngII group was decreased, whereas addition of apelin-13 restored Cx43 expression. Under the treatment of AngII and apelin-13, adding CC or Ra downregulated the expression and distribution of Cx43. **(B, C)** n=6; * $p < 0.05$ vs. AngII+AP; ** $p < 0.01$ vs. AngII; *** $p < 0.001$ vs. Control; &&& $p < 0.001$ vs. AngII+AP.

Rapamycin reversed the downregulation of BNP and cell hypertrophy induced by apelin-13

The protein level of BNP was measured to assess HL-1 cell hypertrophy, (Fig. 4A) and cell immunofluorescence using FITC-phalloidin was performed to assess cytoskeletal structure (Fig. 4B, C).

Western blot analysis showed that apelin-13 decreased the expression of BNP, which was highly increased by rapamycin. Cellular staining with FITC-phalloidin revealed that the effect of apelin-13 on cell size was reversed by rapamycin. However, compound C had no apparent effect.




Fig. 4. The effects of compound C and rapamycin on BNP expression and HL-1 cell size. Compared with the control group, the expression of BNP (**A**) and cell size (**B**, **C**) were increased in AngII group but significantly decreased in the AngII+AP group. Addition of Ra in the AngII+AP group reversed the downregulation of BNP expression and cell size, whereas CC did not significantly affect either BNP expression or cell size. n=6; a: control; b: AngII; c: AngII+AP; d: AngII+AP+CC; e: AngII+AP+RA; *** $p < 0.001$ vs. control; * $p < 0.05$ vs. AngII; &&& $p < 0.001$ vs. AngII+AP.

Discussion

Our study investigated the effects of apelin-13 on Cx43 expression and autophagy induced by AngII and on the AMPK/mTOR signaling pathway, as the potential mechanism. The results demonstrated the following: 1) apelin-13 accentuated the AngII-induced decrease in Cx43 expression in HL-1 cells; 2) apelin-13 reversed the AngII-induced decrease in AMPK expression in HL-1 cells; 3) AMPK/mTOR signaling mediated the protective effect of apelin-13 on Cx43 expression and distribution, and induction of autophagy reversed this effect; 4) AMPK/mTOR signaling mediated the increase in autophagy induced by apelin-13; and 5) apelin-13 prevented the AngII effects on cell hypertrophy, according to BNP expression, and cell size, but induction of autophagy reversed these effects.

AngII participates in a variety of cardiovascular pathophysiological processes that can lead to cardiac arrhythmia, including fibrosis, inflammation, vasoconstriction, cardiac hypertrophy, oxidative stress, ion channel dysfunction and ID protein remodeling (Valls-Lacalle *et al.* 2019). AF is the most common tachyarrhythmia in clinical practice, causing increased mortality and morbidity, and it has a major economic burden (Heijman *et al.* 2015). Activation of the renin-angiotensin system increased the level of AngII in heart tissue and promoted the development of AF (Tsai *et al.* 2008). Researchers have developed a model of AF triggered by AngII in mice, and multiple signaling pathways that stimulate atrial fibrosis, inflammation and oxidative stress, leading to AF inducibility, have been discovered (Li *et al.* 2018). Some studies have used AngII to generate a model of cardiac remodeling in HL-1 cells (Miteva *et al.* 2016). Accordingly, we chose to also use these murine atrial myocytes, which have differentiation potential and maintain spontaneous depolarization, as a model of cell remodeling induced by AngII.

Cx43 is an important component of Intercalated disc protein and has been investigated extensively in the cardiac system. Recent studies discovered that Cx43 abnormal remodeling promoted the development of AF in guinea pig hearts, and the same was found in AF patients (Shinohara *et al.* 2017, Nagibin *et al.* 2016). This indicates that abnormalities in connexin expression and distribution, as factors involved in atrial remodeling, play an important role in AF and may be a potential therapeutic target for AF-induced atrial remodeling. Cx43

expression was decreased by AngII in a concentration-dependent manner, and this effect was prevented by addition of apelin-13.

Apelin, a peptide released from adipose tissue provides a protective effect in many physiological processes (Sörhede *et al.* 2005). With direct effects on cardiomyocyte contractility and electrophysiology, apelin is increasingly being regarded as an important regulator of cardiovascular homeostasis (Farkasfalvi *et al.* 2007). A recent study revealed that the rate of AF was three times higher in patients with low than in those with high apelin levels (Falcone *et al.* 2010). Thus, apelin may have potential predictive and therapeutic effects on AF. Recent study showed that AngII-mediated cardiac dysfunction, hypertrophy and fibrosis were augmented in apelin knockout mice (Sato *et al.* 2019). The apelin gene encodes a 77-amino-acid pre-propeptide, which can be cleaved into different bioactive apelin peptides, including apelin-36, apelin-17 and apelin-13, with apelin-13 being predominant in the heart (Chaves *et al.* 2015). Increased expression of Cx43 induced by apelin has been found in both mouse and human cardiac embryonic stem cells (Wang *et al.* 2017). However, it remains unclear whether apelin-13 can prevent the atrial Cx43 remodeling induced by AngII. We treated HL-1 cells with different concentrations of apelin-13 alone, Western blot analysis showed that the change of Cx43 expression was not obvious. But treated with apelin-13 and AngII together, apelin-13 significantly increased the downregulation of Cx43 expression induced by AngII.

Ye *et al.* (2015) demonstrated that overexpression of apelin abolished the cardiac hypertrophy induced by AngII in cultured cardiomyocytes. A recent study indicated that in AF patients, cardiac production and the circulating level of BNP were increased, and chronic BNP therapy prevented atrial electrical remodeling in both rabbits with rapid atrial pacing and HL-1 cells with rapid field stimulation (Zhao *et al.* 2019). However, the functional significance of BNP in HL-1 cell remodeling remains to be determined. Accordingly, cell immunofluorescence using FITC-phalloidin was performed to visualize the cytoskeleton of HL-1 cells to determine cell size. We measured the BNP level and performed fluorescence staining in HL-1 cells and found that apelin-13 could decrease the expression of BNP and cell hypertrophy induced by AngII, and that autophagy may play an important role.

Studies have shown that autophagy has different effects in different situations, having either a pro-survival

or pro-death effect (Azad *et al.* 2008). A recent study showed that suppression of autophagy may be a promising target in atrial fibrosis and AF (Lin *et al.* 2020). Studies have indicated that Cx43 remodeling is one of the most important processes in atrial remodeling and is also likely to be associated with autophagy, but the mechanism requires further study. Thus, we attempted to identify the mechanism linking Cx43, autophagy and hypertrophy.

Although numerous studies have demonstrated that AMPK-related signaling pathways are involved in AngII-induced inflammation in HL-1 cells (Kim *et al.* 2017), little is known about AngII-induced Cx43 remodeling in HL-1 cells. Our results confirmed that apelin-13 increased AMPK expression, and that compound C reverses this effect. AMPK/mTOR is a major pathway regulating autophagy, thereby affecting cell survival and death. The protective effect of apelin-13 on Cx43 remodeling induced by high glucose was shown to be dependent on the AMPK/mTOR pathway. The AMPK pathway affects Cx43 remodeling, but its effect on AngII-induced Cx43 remodeling in HL-1 cells has not

been investigated. In our study, compound C (AMPK inhibitor) and rapamycin (mTOR inhibitor) were co-treated with apelin-13 to determine whether apelin-13 has a protective or inhibitory effect on AngII-induced Cx43 expression and cell hypertrophy. Our results indicated that apelin-13 has a protective effect on Cx43 expression, cell hypertrophy and autophagy development. Compound C inhibits AMPK activity and the protective role of apelin-13 in Cx43 expression. To evaluate autophagic flux, we used LC3II, which plays a critical role in macroautophagy and is considered a suitable marker of autophagy. LC3II expression was inhibited by compound C, suggesting that AMPK pathway is involved in autophagy activation. However, rapamycin, which inhibits mTOR activity, stimulated autophagy and increased LC3II expression, which could further inhibit Cx43 and AMPK expression and promote cell hypertrophy. These results suggest that increased autophagy has decreasing Cx43 expression and promotes cell hypertrophy. These results suggest that increased autophagy has decreasing Cx43 expression and promotes cell hypertrophy (Fig. 5).

HL-1




Fig. 5. Functional pathway diagram. Schematic representation showing that apelin-13 increased autophagy and Cx43 expression through an AMPK/mTOR signaling pathway but decreased cell hypertrophy in HL-1 cells. In addition, increased autophagy decreased the expression of Cx43 and promoted cell hypertrophy.

Conclusions

AngII decreased Cx43 expression and distribution, stimulated autophagic flux and increased the hypertrophy of HL-1 cells. However, apelin-13 *via* AMPK/mTOR pathway reversed the AngII-induced effects on Cx43 downregulation and cell hypertrophy in HL-1 cells and further increased autophagy, which in turn inhibited Cx43 expression and promoted cell hypertrophy. Thus, it's promising that apelin-13 may be

a potential agent in prevention or treatment of AF in the future.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

This work was supported by a grant from innovation project of postgraduate education in Shanxi Province (No. 2C592019086).

References

- AZAD MB, CHEN Y, HENSON ES, CIZEAU J, McMILLAN-WARD E, ISRAELS SJ, GIBSON SB: Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. *Autophagy* 4: 195-204, 2008. <https://doi.org/10.4161/auto.5278>
- CHAVES-ALMAGRO C, CASTAN-LAURELL I, DRAY C, KNAUF C, VALET P, MASRI B: Apelin receptors: From signaling to antidiabetic strategy. *Eur J Pharmacol* 763: 149-159; 2015. <https://doi.org/10.1016/j.ejphar.2015.05.017>
- CHUGH SS, HAVMOELLER R, NARAYANAN K, SINGH D, RIENSTRA M, BENJAMIN E, GILLUM RF, KIM Y-H, McANULTY JH, ZHENG Z-J, FOROUZANFAR MH, NAGHAVI M, MENSAH G, EZZATI M, MURRAY CJL: Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation* 129: 837-847, 2014. <https://doi.org/10.1161/CIRCULATIONAHA.113.005119>
- FALCONE C, BUZZI MP, D'ANGELO A, SCHIRINZI S, FALCONE R, RORDORF R, CAPETTINI AC, LANDOLINA M, STORTI C, PELISSERO G: Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. *Int J Immunopathol Pharmacol* 23: 917-925, 2010. <https://doi.org/10.1177/039463201002300328>
- FARKASFALVI K, STAGG MA, COPPEN SR, SIEDLECKA U, LEE J, SOPPA GK, MARCZIN N, SZOKODI I, YACIOUB MH, TERRACCIANO CMN: Direct effects of apelin on cardiomyocyte contractility and electrophysiology. *Biochem Biophys Res Commun* 357: 889-895, 2007. <https://doi.org/10.1016/j.bbrc.2007.04.017>
- HEIJMAN J, DOBREV D: Irregular rhythm and atrial metabolism are key for the evolution of proarrhythmic atrial remodeling in atrial fibrillation. *Basic Res Cardiol* 110: 41, 2015. <https://doi.org/10.1007/s00395-015-0498-1>
- KIM N, JUNG Y, NAM M, SUN KANG M, KYUNG LEE M, CHO Y, CHOI E-K, HWANG G-S, SOO KIM H: Angiotensin II affects inflammation mechanisms via AMPK-related signalling pathways in HL-1 atrial myocytes. *Sci Rep* 7: 10328, 2017. <https://doi.org/10.1038/s41598-017-09675-3>
- LESUR O: Myocardial impact and cardioprotective effects of apelin-13 and a c-terminal-modified analog during lps and clp experimental sepsis. *Intensive Care Med* Exp 3 (Suppl 1): A436, 2015. <https://doi.org/10.1186/2197-425X-3-S1-A436>
- LEVINE B, KLIONSKY DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. *Dev Cell* 6: 463-477, 2004. [https://doi.org/10.1016/S1534-5807\(04\)00099-1](https://doi.org/10.1016/S1534-5807(04)00099-1)
- LEYBAERT L, LAMPE PD, DHEIN S, KWAK BR, FERDINANDY P, BEYER EC, LAIRD DW, NAUS CC, GREEN CR, SCHULZ R: Connexins in cardiovascular and neurovascular health and disease: Pharmacological implications. *Pharmacol Rev* 69: 396-478, 2017. <https://doi.org/10.1124/pr.115.012062>
- LI A, ROY S: High glucose-induced downregulation of connexin 43 expression promotes apoptosis in microvascular endothelial cells. *Invest Ophthalmol Vis Sci* 50: 1400-1407, 2009. <https://doi.org/10.1167/iovs.07-1519>
- LI J, WANG S, BAI J, YANG X-L, ZHANG Y-L, CHE Y-L, LI H-H, YANG Y-Z: Novel role for the immunoproteasome subunit PSMB10 in angiotensin II-induced atrial fibrillation in mice. *Hypertension* 71: 866-876, 2018. <https://doi.org/10.1161/HYPERTENSIONAHA.117.10390>
- LI X, YU L, GAO J, BI X, ZHANG J, XU S, WANG M, CHEN M, QIU F, FU G: Apelin ameliorates high glucose-induced downregulation of Connexin 43 via AMPK-dependent pathway in neonatal rat cardiomyocytes. *Aging Dis* 9: 66-76, 2018. <https://doi.org/10.16992/ASOS.13996>
- LIN G, LU HH, SHEN Y, HUANG JF, SHI LS, GUO YN: Meta-analysis of the therapeutic effects of various methods for the treatment of chronic atrial fibrillation. *Exp Ther Med* 6: 489-496, 2013. <https://doi.org/10.3892/etm.2013.1158>
- LIN R, WU S, ZHU D, QIN M, LIU X: Osteopontin induces atrial fibrosis by activating AKT/GSK-3 β / β -catenin pathway and suppressing autophagy. *Life Sci* 245: 117328, 2020. <https://doi.org/10.1016/j.lfs.2020.117328>
- MITEVA K, VAN LINTHOUT S, PAPPITZ K, MÜLLER I, SPILLMANN F, HAAG M, STACHELSCHIED H, RINGE J, SITTINGER M, TSCHÖPE C: Human endomyocardial biopsy specimen-derived stromal cells modulate angiotensin II-induced cardiac remodeling. *Stem Cells Transl Med* 5: 1707-1718, 2016. <https://doi.org/10.5966/sctm.2016-0031>

- NAGIBIN V, EGAN BENOVA T, VICZENCZOVA C, SZEIFFOVA BACOVA B, DOVINOVA I, BARANCIK M, TRIBULOVA N: Ageing related down-regulation of myocardial connexin-43 and up-regulation of MMP-2 may predict propensity to atrial fibrillation in experimental animals. *Physiol Res* 65: 91-100, 2016. <https://doi.org/10.33549/physiolres.933389>
- ROCKEL JS, KAPOOR M: Autophagy: controlling cell fate in rheumatic diseases. *Nat Rev Rheumatol* 13: 193, 2017. <https://doi.org/10.1038/nrrheum.2017.17>
- SATO T, KADOWAKI A, SUZUKI T, ITO H, WATANABE H, IMAI Y, KUBA K: Loss of apelin augments angiotensin II-induced cardiac dysfunction and pathological remodeling. *Int J Mol Sci* 20: 239, 2019. <https://doi.org/10.3390/ijms20020239>
- SHINOHARA D, MATSUSHITA S, YAMAMOTO T, INABA H, KUWAKI K, SHIMADA A, AMANO A: Reduction of c-kit positive cardiac stem cells in patients with atrial fibrillation. *J Cardiol* 69: 712-718, 2017. <https://doi.org/10.1016/j.jicc.2016.07.006>
- SÖRHEDE WM, MAGNUSSON C, AHRÉN B: The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. *Regul Pept* 131: 12-17, 2005. <https://doi.org/10.1016/j.regpep.2005.05.004>
- TANG H, LI J, LIU X, WANG G, LUO M, DENG H: Down-regulation of HSP60 suppresses the proliferation of glioblastoma cells via the ROS/AMPK/mTOR pathway. *Sci Rep* 6: 28388, 2016. <https://doi.org/10.1038/srep28388>
- TATEMOTO K, HOSOYA M, HABATA Y, FUJII R, KAKEGAWA T, ZOU MX, KAWAMATA Y, FUKUSUMI S, HINUMA S, KITADA C, KUROKAWA T, ONDA H, FUJINO M: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. *Biochem Biophys Res Commun* 251: 471-476, 1998. <https://doi.org/10.1006/bbrc.1998.9489>
- TSAI CT, LAI LP, HWANG JJ, CHIANG FT, TSENG CD, LIN JL: Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation. *J Hypertens* 26: 570-582: 2008. <https://doi.org/10.1097/HJH.0b013e3282f34a4a>
- VALLS-LACALLE L, NEGRE-PUJOL C, RODRÍGUEZ C, VARONA S, VALERA-CAÑELLAS A, CONSEGAL M, MARTÍNEZ-GONZÁLEZ J, RODRÍGUEZ-SINOVAS A: Opposite effects of moderate and extreme CX43 deficiency in conditional CX43-deficient mice on angiotensin II-induced cardiac fibrosis. *Cells* 8: 1299, 2019. <https://doi.org/10.3390/cells8101299>
- WANG IN, WANG X, GE X, ANDERSON J, HO M, ASHLEY E: Apelin enhances directed cardiac differentiation of mouse and human embryonic stem cells. *PLoS One* 7: e38328, 2017. <https://doi.org/10.1371/journal.pone.0038328>
- XIAO Y, CAI X, ATKINSON A, LOGANTHA SJ, BOYETT M, DOBRZYNSKI H: Expression of connexin 43, ion channels and Ca²⁺-handling proteins in rat pulmonary vein cardiomyocytes. *Exp Ther Med* 12: 3233-3241, 2016. <https://doi.org/10.3892/etm.2016.3766>
- YANG X, ZHU W, ZHANG P, CHEN K, ZHAO L, LI J, WEI M, LIU M: Apelin-13 stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in myocardial microvascular endothelial cells. *Mol Med Rep* 9: 1590-1596, 2014. <https://doi.org/10.3892/mmr.2014.1984>
- YE L, DING F, ZHANG L, SHEN A, YAO H, DENG L, DING Y: Serum apelin is associated with left ventricular hypertrophy in untreated hypertension patients: *J Transl Med* 13: 290, 2015. <https://doi.org/10.1186/s12967-015-0635-5>
- ZHAO H, LI T, LIU G, ZHANG L, LI G, YU J, LOU Q, HE R, ZHAN C, LI L, YANG W, ZANG Y, CHENG C, LI W: Chronic B-Type natriuretic peptide therapy prevents atrial electrical remodeling in a rabbit model of atrial fibrillation. *J Cardiovasc Pharmacol Ther* 24: 575-585, 2019. <https://doi.org/10.1177/1074248419854749>